- Price
- $65.34
- Day
- -1.30%
- Mkt Cap
- $20.49B
- 52W Range
- $65.14 – $80.36
- Volume
- 5.81M
- Beta
- 0.33
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Corient Private Wealth LP reduced its stake in CMS Energy Corporation (NYSE: CMS) by 5.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 147,623 shares of the utilities provider's stock after selling 8,599 shares during the quarter. Corient Private Wealth LP's holdings
Read full article
Shares of CMS Energy Corporation (NYSE: CMS - Get Free Report) reached a new 52-week low during trading on Thursday. The stock traded as low as $65.67 and last traded at $65.9950, with a volume of 2050103 shares. The stock had previously closed at $65.92. Analyst Ratings Changes Several research firms have commented on CMS.
Read full article
CMS Energy remains positioned to become a Dividend Aristocrat early next decade. The regulated utility topped the analyst consensus for both operating revenue and adjusted EPS in the second quarter. CMS Energy possesses a BBB S&P credit rating with a stable outlook.
Read full article
Nykredit A S bought a new stake in CMS Energy Corporation (NYSE: CMS) in the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 17,941 shares of the utilities provider's stock, valued at approximately $1,372,000. A number of other institutional investors and hedge funds also recently bought and
Read full article
SHENZHEN, CHINA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited) received the approval from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (Lumirix®) for the treatment of mild to moderate atopic dermatitis (“AD”) on 2 September 2026. The drug registration certificate was obtained on 3 September 2026. The product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Read full article